miR-26a exerts broad-spectrum antiviral effects via the enhancement of RIG-I-mediated type I interferon response by targeting USP15

Microbiol Spectr. 2024 Jan 11;12(1):e0312423. doi: 10.1128/spectrum.03124-23. Epub 2023 Nov 29.

Abstract

miR-26a serves as a potent positive regulator of type I interferon (IFN) responses. By inhibiting USP15 expression, miR-26a promotes RIG-I K63-ubiquitination to enhance type I IFN responses, resulting in an active antiviral state against viruses. Being an intricate regulatory network, the activation of type I IFN responses could in turn suppress miR-26a expression to avoid the disordered activation that might result in the so-called "type I interferonopathy." The knowledge gained would be essential for the development of novel antiviral strategies against viral infection.

Keywords: RIG-I; USP15; broad spectrum; innate immunity; miR-26a; ubiquitination.

MeSH terms

  • Antiviral Agents / pharmacology
  • DEAD Box Protein 58 / metabolism
  • Immunity, Innate
  • Interferon Type I*
  • MicroRNAs* / genetics
  • Signal Transduction

Substances

  • Interferon Type I
  • DEAD Box Protein 58
  • MicroRNAs
  • Antiviral Agents